Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PRKCI (ImmuneEditome ID:5584)

1. Gene summary of enriched editing regions for PRKCI

Gene summary

Gene information	Gene symbol	PRKCI
	Gene ID	5584
	GeneSynonyms	DXS1179E\|PKCI\|nPKC-iota
	GeneCytomap	3q26.2
	GeneType	protein-coding
	GeneDescription	protein kinase C iota type\|PRKC-lambda/iota\|aPKC-lambda/iota\|atypical protein kinase C-lambda/iota
	GeneModificationdate	20230410
	UniprotID	P41743
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr3:170236153-170236897:+	ENST00000295797.4	ENSG00000163558.11	PRKCI	intronic	AluJr,AluSz6	chr3:170236153-170236897:+.alignment
chr3:170241691-170242415:+	ENST00000295797.4	ENSG00000163558.11	PRKCI	intronic	AluJb,AluJr,AluSp	chr3:170241691-170242415:+.alignment
chr3:170247106-170247694:+	ENST00000295797.4	ENSG00000163558.11	PRKCI	intronic	AluSp,AluJo	chr3:170247106-170247694:+.alignment
chr3:170278447-170279189:+	ENST00000295797.4	ENSG00000163558.11	PRKCI	intronic	(ATT)n,MSTB,AluJb,AluJr	chr3:170278447-170279189:+.alignment
chr3:170285105-170289628:+	ENST00000295797.4	ENSG00000163558.11	PRKCI	intronic	AluY,(CTTTTCT)n,AluSq2,AluSz,L1MC5a,L1M5,FLAM_A,AluJb,(AT)n,L1ME4b,AluSx,AluSz6	chr3:170285105-170289628:+.alignment
chr3:170289939-170291064:+	ENST00000295797.4	ENSG00000163558.11	PRKCI	intronic	AluSp,L1M5,AluSz6,(TC)n,(AT)n	chr3:170289939-170291064:+.alignment
chr3:170293733-170293910:+	ENST00000476635.4	ENSG00000163558.11	PRKCI	ncRNA_intronic	AluSz	chr3:170293733-170293910:+.alignment
chr3:170293733-170293910:+	ENST00000483697.2	ENSG00000163558.11	PRKCI	ncRNA_intronic	AluSz	chr3:170293733-170293910:+.alignment
chr3:170293733-170293910:+	ENST00000485837.4	ENSG00000163558.11	PRKCI	ncRNA_intronic	AluSz	chr3:170293733-170293910:+.alignment
chr3:170294982-170295803:+	ENST00000476635.4	ENSG00000163558.11	PRKCI	ncRNA_intronic	AluSx1,AluSz,AluJb	chr3:170294982-170295803:+.alignment
chr3:170294982-170295803:+	ENST00000483697.2	ENSG00000163558.11	PRKCI	ncRNA_intronic	AluSx1,AluSz,AluJb	chr3:170294982-170295803:+.alignment
chr3:170294982-170295803:+	ENST00000485837.4	ENSG00000163558.11	PRKCI	ncRNA_intronic	AluSx1,AluSz,AluJb	chr3:170294982-170295803:+.alignment

Top

2. Tumor-specific enriched editing regions for PRKCI

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

StageType

AnovaP

Boxplot

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for PRKCI

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr3:170285105-170289628:+

ESCA

EER

ENSG00000156381,ANKRD9

0.3200

3.7271e-02

2.3649e-06

0.4255

CSTF2T;DKC1;ELAVL1;EWSR1;FUS;IGF2BP2;TAF15

NK_cells_activated

GSVA_HALLMARK_P53_PATHWAY

More results

Top

4. Enriched editing regions and immune related splicing for PRKCI

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr3:170285105-170289628:+

ESCA

EER

ENSG00000170854.13

chr3

97950785:97950888:97949843:97950012:97949843:97950015

0.4352

8.7444e-03

3.8823e-06

0.4172

CSTF2T;DKC1;ELAVL1;EWSR1;FUS;IGF2BP2;TAF15

Macrophages_M0

GSVA_HALLMARK_HYPOXIA

ENSG00000163558.11,PRKCI

ESCA

EAG

ENSG00000170854.13

chr3

97950785:97950888:97949843:97950012:97949843:97950015

0.5217

2.6579e-04

1.1750e-08

0.4917

ADAR;AIFM1;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDF1;ZC3H7B;ZNF184

Macrophages_M0

GSVA_HALLMARK_HYPOXIA

ENSG00000163558.11,PRKCI

ESCA

EAG

ENSG00000130764.5

chr1

3780219:3781326:3781511:3781601

-0.1863

7.2312e-03

4.3919e-05

-0.4125

ACIN1;ADAR;AIFM1;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;ZC3H7B;ZNF184

NK_cells_activated

GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS

ENSG00000163558.11,PRKCI

ESCA

EAG

ENSG00000158292.6

chr1

6260824:6260975:6254549:6255014:6254549:6255122

-0.4009

2.9177e-03

2.1294e-06

-0.4399

ADAR;AIFM1;CELF2;CNBP;CSTF2T;DDX3X;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28A;MOV10;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;SLTM;SRSF1;SRSF3;TAF15;TARBP2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184

Eosinophils

GSVA_HALLMARK_P53_PATHWAY

ENSG00000163558.11,PRKCI

ESCA

EAG

ENSG00000159692.11

chr4

1213477:1213605:1214190:1214473

-0.3934

3.0131e-02

7.1499e-06

-0.4001

ACIN1;ADAR;AIFM1;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184

CTBP1

T_cells_CD4_memory_resting

GSVA_HALLMARK_MTORC1_SIGNALING

ENSG00000163558.11,PRKCI

ESCA

EAG

ENSG00000127415.8

chr4

1000611:1001881:1001981:1002003

-0.4757

1.4527e-03

6.8529e-06

-0.4009

ACIN1;ADAR;AIFM1;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184

Eosinophils

GSVA_HALLMARK_APICAL_JUNCTION

ENSG00000163558.11,PRKCI

EAG

ENSG00000156976.10

chr3

186787802:186788420:186789124:186789140

-0.3592

4.5974e-05

2.2088e-10

-0.4036

ACIN1;ADAR;AIFM1;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL14;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184

T_cells_CD8

GSVA_HALLMARK_DNA_REPAIR

ENSG00000163558.11,PRKCI

EAG

ENSG00000121310.12

chr1

52904645:52905090:52906518:52906611

-0.3478

4.9660e-05

8.2807e-11

-0.4147

ADAR;BUD13;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP3;ILF3;KHSRP;LARP7;LIN28B;MBNL2;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM5;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YTHDC1

T_cells_CD8

GSVA_HALLMARK_FATTY_ACID_METABOLISM

chr3:170285105-170289628:+

EER

ENSG00000100823.7

chr14

20455226:20455773:20455913:20456031

-0.3361

1.2872e-04

5.8832e-11

-0.4203

CSTF2T;DKC1;ELAVL1;EWSR1;FUS;IGF2BP2;TAF15

Macrophages_M1

GSVA_HALLMARK_UV_RESPONSE_UP

ENSG00000163558.11,PRKCI

EAG

ENSG00000196923.9

chr5

177491403:177491995:177492404:177492435

-0.3008

2.5476e-04

6.8055e-10

-0.4149

ACIN1;ADAR;AIFM1;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184

PDLIM7

T_cells_CD8

GSVA_HALLMARK_UV_RESPONSE_UP

More results

Top

5. Enriched editing regions and immune infiltration for PRKCI

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr3:170285105-170289628:+	BRCA	EER	NK_cells_activated	4.6442e-02	-0.3940
ENSG00000163558.11,PRKCI	BRCA	EAG	Dendritic_cells_resting	1.1813e-02	0.4773
chr3:170247106-170247694:+	ESCA	EER	Mast_cells_resting	3.0936e-02	-0.4607
ENSG00000163558.11,PRKCI	LUSC	EAG	Macrophages_M1	1.1644e-02	0.4544
chr3:170247106-170247694:+	OV	EER	Neutrophils	8.6060e-03	0.3914
chr3:170285105-170289628:+	OV	EER	Dendritic_cells_resting	6.1675e-04	0.2266
chr3:170289939-170291064:+	OV	EER	T_cells_CD4_memory_resting	2.7705e-02	-0.3320
ENSG00000163558.11,PRKCI	OV	EAG	Dendritic_cells_resting	1.6720e-04	0.2462
chr3:170241691-170242415:+	STAD	EER	T_cells_CD8	2.8361e-02	0.2905
chr3:170285105-170289628:+	STAD	EER	NK_cells_activated	4.3938e-02	0.1670
ENSG00000163558.11,PRKCI	STAD	EAG	T_cells_CD4_memory_resting	8.0464e-03	-0.1959
chr3:170285105-170289628:+	THCA	EER	Eosinophils	2.8637e-02	-0.4774
ENSG00000163558.11,PRKCI	THCA	EAG	Mast_cells_resting	3.8041e-02	-0.4554

Top

6. Enriched editing regions and immune gene sets for PRKCI

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr3:170285105-170289628:+	BRCA	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	2.5673e-05	0.7272
ENSG00000163558.11,PRKCI	BRCA	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	2.3415e-04	0.6512
chr3:170285105-170289628:+	ESCA	GSVA_HALLMARK_P53_PATHWAY	EER	1.0542e-03	0.3029
ENSG00000163558.11,PRKCI	ESCA	GSVA_HALLMARK_P53_PATHWAY	EAG	5.8752e-05	0.3583
ENSG00000163558.11,PRKCI	LUAD	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.9255e-02	0.3883
ENSG00000163558.11,PRKCI	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	9.4896e-03	0.4658
chr3:170289939-170291064:+	OV	GSVA_HALLMARK_DNA_REPAIR	EER	2.9935e-02	0.3276
chr3:170285105-170289628:+	OV	GSVA_HALLMARK_APOPTOSIS	EER	2.3200e-05	0.2781
chr3:170294982-170295803:+	OV	GSVA_HALLMARK_P53_PATHWAY	EER	1.4967e-03	0.3335
chr3:170236153-170236897:+	OV	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	2.2289e-02	0.3105
chr3:170247106-170247694:+	OV	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.5485e-02	0.3179
ENSG00000163558.11,PRKCI	OV	GSVA_HALLMARK_APOPTOSIS	EAG	1.1149e-05	0.2858
ENSG00000163558.11,PRKCI	STAD	GSVA_HALLMARK_APOPTOSIS	EAG	3.3673e-04	0.2629
chr3:170285105-170289628:+	STAD	GSVA_HALLMARK_HYPOXIA	EER	4.7509e-02	0.1643
chr3:170236153-170236897:+	STAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.3999e-03	0.4771
chr3:170285105-170289628:+	THCA	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.8711e-02	0.5080
ENSG00000163558.11,PRKCI	THCA	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	2.1097e-02	0.4996

Top

7. Enriched editing regions and drugs for PRKCI

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr3:170285105-170289628:+	BRCA	Lapatinib	EER	4.9915e-04	-0.6345
ENSG00000163558.11,PRKCI	BRCA	ATRA	EAG	6.0676e-03	0.5142
chr3:170285105-170289628:+	ESCA	ABT.263	EER	4.2422e-03	0.2671
chr3:170247106-170247694:+	ESCA	Bleomycin	EER	8.5627e-03	-0.5460
ENSG00000163558.11,PRKCI	ESCA	CGP.60474	EAG	5.9102e-04	-0.3092
ENSG00000163558.11,PRKCI	LUAD	AG.014699	EAG	3.1555e-02	0.3590
chr3:170289939-170291064:+	OV	Erlotinib	EER	1.3251e-02	0.3707
chr3:170285105-170289628:+	OV	AZ628	EER	1.4350e-05	-0.2848
chr3:170294982-170295803:+	OV	FTI.277	EER	1.5327e-02	-0.2578
chr3:170236153-170236897:+	OV	Cisplatin	EER	8.0029e-03	-0.3572
chr3:170247106-170247694:+	OV	BMS.754807	EER	6.4413e-05	0.5651
ENSG00000163558.11,PRKCI	OV	AZ628	EAG	2.6893e-06	-0.3044
ENSG00000163558.11,PRKCI	STAD	BMS.509744	EAG	5.2287e-03	-0.2062
chr3:170285105-170289628:+	STAD	BMS.509744	EER	1.4153e-02	-0.2027
chr3:170294982-170295803:+	STAD	AZD8055	EER	1.9807e-03	-0.5883
chr3:170236153-170236897:+	STAD	AZD6482	EER	3.2156e-02	-0.3312
chr3:170285105-170289628:+	THCA	Midostaurin	EER	8.7374e-03	-0.5569
ENSG00000163558.11,PRKCI	THCA	Doxorubicin	EAG	1.9035e-02	-0.5068

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER	ENST	UniprotID	DrugBankID	Drug	DrugType
chr3:170236153-170236897:+	ENST00000295797.4	P41743	DB00675	Tamoxifen	SmallMoleculeDrug
chr3:170236153-170236897:+	ENST00000295797.4	P41743	DB04209	Dequalinium	SmallMoleculeDrug
chr3:170236153-170236897:+	ENST00000295797.4	P41743	DB09096	Benzoyl peroxide	SmallMoleculeDrug
chr3:170236153-170236897:+	ENST00000295797.4	P41743	DB12010	Fostamatinib	SmallMoleculeDrug
chr3:170241691-170242415:+	ENST00000295797.4	P41743	DB00675	Tamoxifen	SmallMoleculeDrug
chr3:170241691-170242415:+	ENST00000295797.4	P41743	DB04209	Dequalinium	SmallMoleculeDrug
chr3:170241691-170242415:+	ENST00000295797.4	P41743	DB09096	Benzoyl peroxide	SmallMoleculeDrug
chr3:170241691-170242415:+	ENST00000295797.4	P41743	DB12010	Fostamatinib	SmallMoleculeDrug
chr3:170247106-170247694:+	ENST00000295797.4	P41743	DB00675	Tamoxifen	SmallMoleculeDrug
chr3:170247106-170247694:+	ENST00000295797.4	P41743	DB04209	Dequalinium	SmallMoleculeDrug
chr3:170247106-170247694:+	ENST00000295797.4	P41743	DB09096	Benzoyl peroxide	SmallMoleculeDrug
chr3:170247106-170247694:+	ENST00000295797.4	P41743	DB12010	Fostamatinib	SmallMoleculeDrug
chr3:170278447-170279189:+	ENST00000295797.4	P41743	DB00675	Tamoxifen	SmallMoleculeDrug
chr3:170278447-170279189:+	ENST00000295797.4	P41743	DB04209	Dequalinium	SmallMoleculeDrug
chr3:170278447-170279189:+	ENST00000295797.4	P41743	DB09096	Benzoyl peroxide	SmallMoleculeDrug
chr3:170278447-170279189:+	ENST00000295797.4	P41743	DB12010	Fostamatinib	SmallMoleculeDrug
chr3:170285105-170289628:+	ENST00000295797.4	P41743	DB00675	Tamoxifen	SmallMoleculeDrug
chr3:170285105-170289628:+	ENST00000295797.4	P41743	DB04209	Dequalinium	SmallMoleculeDrug
chr3:170285105-170289628:+	ENST00000295797.4	P41743	DB09096	Benzoyl peroxide	SmallMoleculeDrug
chr3:170285105-170289628:+	ENST00000295797.4	P41743	DB12010	Fostamatinib	SmallMoleculeDrug
chr3:170289939-170291064:+	ENST00000295797.4	P41743	DB00675	Tamoxifen	SmallMoleculeDrug
chr3:170289939-170291064:+	ENST00000295797.4	P41743	DB04209	Dequalinium	SmallMoleculeDrug
chr3:170289939-170291064:+	ENST00000295797.4	P41743	DB09096	Benzoyl peroxide	SmallMoleculeDrug
chr3:170289939-170291064:+	ENST00000295797.4	P41743	DB12010	Fostamatinib	SmallMoleculeDrug